Clinical Trials Browser

Neoplasm Metastasis, Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast

Breast Neoplasms

NCT00253422 2025-06-04

SoFEA

Phase 3 Completed

698 enrolled 19 charts

Breast

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Phase 3 Completed

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT05054751 2024-10-10

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

275 enrolled

Breast

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

Phase 3 Completed

287 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02422615 2023-11-30

MONALEESA-3

Phase 3 Completed

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT03447132 2023-03-10

SAFIA

Phase 3 Completed

354 enrolled

Breast

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

41 enrolled

Breast

Breast Neoplasms

NCT01610284 2020-08-25

BELLE-2

Phase 3 Completed

1,147 enrolled 20 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Phase 3 Completed

295 enrolled 18 charts

Breast

Breast Neoplasms

NCT01300351 2015-04-24

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

Phase 3 Completed

249 enrolled 16 charts

Breast

Breast Neoplasms

NCT00065325 2015-02-24

EFECT

Phase 3 Completed

694 enrolled

Breast

Breast Neoplasms

NCT00256698 2012-08-01

FACT

Phase 3 Completed

514 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT00241449 2012-06-06

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Phase 3 Completed

51 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00327769 2011-01-25

Faslodex Advanced Breast Cancer Local Chinese Study

Phase 3 Completed

234 enrolled

Breast

Advanced Breast Cancer

NCT00635713 2009-04-10

Second Line Breast Cancer Trial

Phase 3 Completed

588 enrolled

Breast

Advanced Breast Cancer

Clinical Trials

FALCON

EMERALD

SoFEA

SOLAR-1

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

PEARL

BioItaLEE

MONALEESA-3

SAFIA

RIBBIT

BELLE-2

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

EFECT

FACT

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Faslodex Advanced Breast Cancer Local Chinese Study

Second Line Breast Cancer Trial